You are here

COLORECTAL CARCINOMA IS ONE OF THE MOST PREVALENT AND LETHAL CANCERS IN THE UNITED STATES.

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 3053
Amount: $41,557.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1985
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
2990 Anthony Road
Burlington, NC 27215
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 WILLIAM D. CLARK
 PRINCIPAL INVESTIGATOR
 (919) 226-6311
Business Contact
Phone: () -
Research Institution
N/A
Abstract

COLORECTAL CARCINOMA IS ONE OF THE MOST PREVALENT AND LETHAL CANCERS IN THE UNITED STATES. ACCORDING TO THE AMERICAN CANCER SOCIETY, THERE ARE 130,000 NEW CASES EACH YEAR. EARLY DIAGNOSIS IS DIFFICULT AND THERE IS NO DIAGNOSTIC TEST WITH A HIGH POSITIVE PREDICTIVE VALUE IN THE EARLY STAGES OF THE DISEASE. DEVELOPMENT OF A TEST THAT DETECTS EARLY COLORECTAL CARCINOMA WOULD SIGNIFICANTLY REDUCE MORBIDITY AND MORTALITY. TESTING THE FEASIBILITY OF A MONOCLONAL-BASED SERUM TEST FOR A COLORECTAL CARCINOMA MARKER IS NOW WARRANTED. MONOCLONAL ANTIBODIES GENERATED AGAINST CRUDE EXTRACTS OF COLORECTAL CARCINOMA CELLS OR FROM HOMOGENATES OF COLORECTAL CELL CULTURES HAVE BEEN PRODUCED BY A NUMBER OF DIFFERENT INVESTIGATORS. SOME MONOCLONAL ANTIBODIES WITH POTENTIAL FOR A RAPID TEST HAVE BEEN DEVELOPED BY CHAN'S GROUP AT M.D. ANDERSON. GRANITE DIAGNOSTICS PROPOSES TO EVALUATE THESE ANTIBODIES TO DETECT THE RELEVANT ANTIGEN(S) IN URINE AND/OR SERUM SAMPLES AND TO DEVELOP A TEST FOR EARLY DIAGNOSIS OF COLORECTAL CARCINOMA. FAVORABLE RESULTS IN PHASE I RESEARCH WILL LEAD TO PHASE II DEVELOPMENT AND TESTING OF A MARKETABLE KIT.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government